General

O’Brien E. The Fibrinolytic System in Arteriosclerosis. J Irish Med Ass 1969;62:203-212.

O’Brien E, Thornes RD, O’Brien D, Hogan B. Inhibition of Antiplasmin and Fibrinolytic Effect of Protease in Patients with Cancer. Lancet 1969;1:173-176.

O’Brien E, Thornes RD. Physiology of Fibrinolysis: The effect of Exercise on Fibrinolysis in Health and Multiple Sclerosis. Ir J Med Sci 1969;1:195-202.

O’Brien E, Clery AP,Thornes RD. Dose Prediction of Streptokinase in Patients undergoing surgery. J Royal Coll Surg Ireland 1969;4:105-109.

Huang CL, O’Brien E, Thornes RD. The Thrombolytic Action of Protease on Experimentally Produced Venous Thrombi the Dog. Ir J Med Sci 1969;2:378-379.

Eddy JD, O’Brien ET, Singh SP. Glucagon and Haemodynamics of Acute Myocardial Infarction. Brit Med J 1969;4:663-665.

O’Brien ET, MacKinnon J. Propranolol and Polythiazide in Treatment of Hypertension. Brit Heart J 1972;34:1042-1044.

O’Brien E. Glucagon in the Treatment of Cardiogenic Shock Following Acute Myocardial Infarction. J Ir Med Ass 1973;66:415-417.

O’Brien E. Advantages and Disadvantages of Beta-adrenergic blocking drugs. Angiology 1978;29:332.

O’Malley K, O’Boyle C, McGarry K, O’Brien E. Vasodilators in the Treatment of Hypertension. In: Pathophysiology and Management of Hypertension. Ed. I. Robertson. Royal Society of Medicine, International Congress & Symposium Series. 1979. pp. 73-81.

O’Boyle C, Kelly J, O’Brien E, O’Malley K. Once-daily slow-release Hydralazine in Hypertension. Topics in Cardiovascular Medicine: Royal Society of Medicine, International Congress & Symposium Series. No. 34. 1979. pp.7-10.

O’Malley K, O’Hanrahan M, O’Boyle C, Laher M, O’Brien E. Compliance with Antihypertensive Therapy in a Limited Eligibility Health Care System. J Ir Med Assoc 1980;73:484-488.

O’Malley K, O’Boyle C, Kelly J. McNay L, O’Brien E. The Clinical Pharmacology of Vasodilator Antihypertensive Drugs. Archives Internationales de Pharmacodynamie. Suppl. 1980;95-103.

O’Boyle C, O’Brien E, O’Malley K. Drug Interactions Involving Vasodilators and Alpha-adrenoceptor Blocking Drugs. In: Clinically Important Adverse Drug Interactions. Ed. JC Petrie. 1980. Elsevier Biomedical Press. pp.131-140.

O’Malley K, Laher M, O’Brien ET. Hypertension in the Elderly. In: Arterial Hypertension. Ed. M. Velasio. Exercpta Medica. Amsterdam. 1980. pp.320-325.

O’Boyle C, Kelly J, O’Brien E, O’Malley K. Once-daily Slow-release Hydralazine in Hypertension. Ir Med J 1981;74:115-116.

Fitzgerald D, O’Brien E, O’Malley K. Vasodilators in the Management of Hypertension. Proceedings of the 8th Congress of Nephrology 1981.471-477.

O’Boyle CP, Kelly J, O’Brien ET, O’Malley K. Once-daily Slow-release Hydralazine in Hypertension. Topics in Cardiovascular Medicine. Royal Society of Medicine International Congress and Symposium Series No. 34. 1981

O’Boyle C, Laher M, O’Brien E, O’Malley K, Kelly J. The Clinical Pharmacology of Tolmesoxide. EurJ Clin Pharmacol 1982;23:93-97.

Fitzgerald D, O’Callaghan WG, O’Malley K, Horgan J, O’Brien E. Clinical and Haemodynamic Responses to Captopril and Hydralazine in Chronic Congestive Heart Failure: The Importance of Preload Reduction. Br J Clin Pharmacol 1982;14:217S-222S.

O’Malley K, O’Brien. Biochemistry and Pharmacology of Hypertension. Biochemical Society Transactions 1982;164-165.

Kelly JG, McGarry K, O’Malley K, O’Brien E. Bioavailability of Labetolol increases with Age. Br J Clin Pharmacol 1982;14:304-305.

O’Malley K, O’Callaghan W, O’Brien E. Hypertension in the Elderly: An Overview. Current Medical Research and Opinion 1982;7 (Suppl):53-60.

McGarry K, Laher MS, Fitzgerald DG, Horgan J, O’Brien E, O’Malley K. Baroreflex Function in Elderly Hypertensives. Hypertension 1983;5:763-766.

O’Malley K, O’Callaghan WG, Laher MS, McGarry K, O’Brien E. B-Adrenoceptor Blocking Drugs and Renal Blood Flow with Special Reference to the Elderly. Drugs 1983;Suppl 2:103-107.

O’Malley K, O’Brien E. Renal effects of Antihypertensive Drugs in Elderly Hypertensives. Acta Med Scand 1983;Suppl 676:110-118.

O’Brien ET, O’Boyle CP, Fitzgerald D, Kelly JG, O’Malley K. Efficaté de l’indapamide dans l’hypertension artérielle mal contrôlée par les béta-bloquers. Le Journal International de Médicine 1983;8:23-27.

O’Callaghan WG, Laher MS, McGarry K, O’Brien E, O’Malley K. Antihypertensive and Renal Haemodynamic Effects of Atenolol and Nadolol in Elderly Hypertensive Patients. Br J Clin Pharmacol 1983;16:417.

O’Boyle C, Fitzgerald D, Kelly JG, O’Malley K, O’Brien E. The Efficacy of Indapamide in Hypertensive Patients Failing to Respond to a B-blocker Alone. Drugs of Today 1984;20:27-31.

O’Callaghan WG, O’Brien E, O’Malley K. Hypertension in the Elderly: Epidemiology, Pathophysiology and Management. In: Clinical Pharmacology and Drug treatment. Ed. K. O’Malley. Churchill Livingstone. Edinburgh. 1984.pp.12-138.

O’Malley K, McGarry K, O’Callaghan WG, Kelly JG, O’Brien E. Clinical Pharmacology of Labetolol in Elderly Hypertensives. In: Balanced Alpha/Beta Blockade of Adrenoceptors. A Rational Therapeutic Concept in the Treatment of Hypertension and Coronary Heart Disease. Eds. N. Rietbrock and B. G. Woodcock. Friedr Vieiveg and Sohn. Braunschweig/Wisbaden 1984. pp.131-141.

O’Malley K, O’Callaghan WG, O’Brien E. Preventing the Age Risk in Blood Pressure: Relevance, Feasibility and Methods. In: Frontiers in Cardioogy for the 80s. Academic Press. 1984. London. pp.29-34.

O’Malley K, O’Brien E. Drug Treatment of Hypertension in the Elderly. In: Hypertension and Coronary Heart Disease. Eds. A.J.M. Donkers and M.D. van Damne. Netherlands. 1984. pp.161-170.

Meagher F, O’Brien E, O’Malley K. Compliance in Elderly Hypertensives. J Hypertens 1985;3(Suppl 1):41-43.

O’Brien E. The Management of Hypertension in the Elderly. In; Therapeutics in the Elderly. Scientific Foundations and Clinical Practice. Proceedings of the Symposium on `Pharmacology and Therapeutics in the Elderly’. Eds: K. O’Malley and J.L. Waddington. Excerpta Medica. Amsterdam. 1985. pp.213-221.

O’Malley K, O’Brien E, Fitzgerald D, Kelly JG. Adrenoceptors and Hypertension. In: Pharmacology of Adrenoceptors. Eds: E. Szabadi, C.M. Bradshaw, S.R. Nahorski. Macmillan. London. 1985. pp.197-204

Brennan M, O’Brien E, O’Malley K. The effect of age on Blood Pressure and Heart Rate Variability in Hypertension. J Hypertens 1986;4(Suppl 6):S269-S272.

Harrington K, Fitzgerald P, O’Donnell D, Hill KW, O’Brien E, O’Malley K. Short and Long Term Treatment of Essential Hypertension with Felodipine as monotherapy. Drugs 1987;34(Suppl 3)178-185.

Cox JP, O’Brien E, O’Malley K. Treatment of Elderly Hypertensives: Results and Conclusions of Recent Trials. J Cardiovasc Pharmacol 1987;10(Suppl 2):S65-S70.

Cox J P, O’Boyle C A, Mee F, Kelly J, Atkins N, Coakley D, O’Brien E, O’Malley K. The antihypertensive efficacy of verapamil in the elderly evaluated by ambulatory blood pressure measurement. J Human Hypertens 1988:2:41-47

O’Brien E, O’Malley K. Overtreating hypertension . Br Med J 1988;297:1607.

McCormack PME, Latham AN, Mee F, Atkins N, O’Brien E, O’Malley K. The Efficacy and Duration of Action of Sustained-Release Verapamil in Essential Hypertension. J Cardiovasc Pharmacol 1989;(Suppl.4)13:S34-S37.

Cox JP, Ryan J, O’Brien E, O’Malley K. The effect of slow-release nicardipine on ambulatory and clinic blood pressure in mild hypertension. Br J Clin Pharmacol 1989;28:79-82.

Cox JP, Duggan J, O’Boyle CA, Mee F, Walsh JB, Coakley D, O’Brien E, O’Malley K. A double-blind evaluation of captopril in elderly hypertensives. J Hypertens 1989;7:299-303.

Cox JP, O’Brien E, O’Malley K. Management of hypertension in the elderly. In; New Frontiers in Cardiovascular Therapy: Focus on Angiotensin Converting Enzyme Inhibition. Eds. E.H.Sonneblick, J.H.Laragh, M.Lesch. Excerpta Medica. Holland. 1988. pp.157-164

Duggan J, Kilfeather S, Lightman SL, O’Brien E, O’Malley K. Plasma atrial natruiretic peptide concentration and platelet atrial natrurietic peptide binding site density in ageing and hypertension. Clin Sci 1991;81 :509-514

Duggan J, Kilfeather S, O’Brien E, O’Malley K. The effects of age on platelet intracellular free calcium concentration in normotensives and hypertensives. J Hypertens 1991;9:845-850

Duggan J, Kilfeather S, O’Brien E, O’Malley K, Nussberger J. Effects of Ageing and Hypertension on Plasma Angiotensin II and Platelet Angiotensin II Receptor Density. Am J Hypertens 1992;5:687-693.

Cox J, O’Malley K, O’Brien E. The J-curve in elderly hypertensives. J Hypertens 1992;10(suppl 2):S17-S23

Duggan J, Nussberger J, Kilfeather S, O’Malley K. Ageing and Human Hormonal and Pressor Responsiveness to Angiotensin II Infusion With Simultaneous Measurement of Exogenous and Endogenous Angioitensin II. Am J Hypertens 1993;6:641-647.

Staessen J, Birkenhager WH, Dollery C, Fagard R. Treatment of hypertension in elderly patients. Lancet 1997;350:1632-1634.

Owens P, O’Brien E. The Calcium Channel Blocker Debate. Ir Med J 1998;91:158-161

Kostis JB, Omalley K, O’Brien E. The Elderly. In: The ABCs of Antihypertensive Therapy. Ed. Franz H. Messerli. Second Edition. Lippincvott Williams & Wilkins. New York.1999. Pp. 246-254

Owens P, Kelly L, Nallen R, Ryan D, Fitzgerald D, O’Brien. Comparison of anti-hypertensive and metabolic effects of losaratn and losartan in combination with hydrochlorathiazide: a randomized controlled trial. J Hypertens 2000:18;339-345

Staessen JA, Kuznetsova T, Accetor R, Bacchieri A, Brand E, Burnier M, Celis H, Citterios L, de Leeuw PW, Filipovsky J, Fournier A, Kawecka-Jaszcz k, Manunta P, Nikitin Y, O’Brien ET, Redon J, Thijs L, Ferrari P, Valentini G, Bianchi G, on behalf of the OASIS-HT Investigators. Ouabain and Adducin for Specific Intervention on Sodium in HyperTensio (OASIS-HT): design of a pharmacogenic dose-finding study. Pharmacogenomics 2005;6:755-775